International Biotechnology Trust plc - IBT

Investing in biotechnology for a healthier future

Access the fast-growing biotechnology sector through an actively managed, diversified investment trust

Targeting high growth, International Biotechnology Trust plc (IBT) backs innovative companies addressing high unmet medical needs and offers investors the opportunity for financial returns.

Behind the trust - read our philosophy article >

Seeking the best in biotech

International Biotechnology Trust invests in around 100 of the most innovative, high quality quoted and unquoted companies across the entire spectrum of the biotech and other life sciences sectors.

A keen focus on risk management

An acute understanding of valuation and the biotechnology investment cycle informs the managers’ top down overlay and they take prudent steps to reduce individual company risk ahead of binary events. This has contributed to their outperformance against the index and their peers.

Income generating

A dividend of 4% of closing net asset value, paid biannually, offers investors a highly differentiated and reliable source of income.

Portfolio Company Updates

Novartis to acquire Avidity Biosciences - October 2025
Novo Nordisk to acquire Akero - October 2025
Genmab to acquire Merus - September 2025
Pfizer agrees to acquire Metsera - September 2025
Acquisition of 89Bio by Roche - September 2025
Merck to acquire Verona Pharma - July 2025
Sanofi to acquire Blueprint Medicines - June 2025
Merck to acquire SpringWorks - April 2025
Acquisition of Intra-Cellular Therapies by Johnson & Johnson - January 2025

Download Key Material

IBT Outlook 2026
Annual Report and Accounts 2025
Half Year Report & Accounts 2025
Factsheet
Kepler Research
Key Information Document

Portfolio & Performance Hub

Schroder ISF GTR MStar Rating 5 stars

Source: Morningstar, February 2026

Association of Investment Companies ISA Millionaire Logo for 2026. An investment in this trust since 1995, using your full ISA allowance every year, would now result in you having over one million pounds thanks to the long terms growth potential and powerful compounding of these vehicle

Source: Association of Investment Companies, 2026

citywire aa rating

Source: Citywire, 2026

Income 2026 badge

In the Media

Interactive Investor: Investment trust winners and losers in 2025
Trustnet: The best funds and trusts in November 2025
Kepler: Results Analysis
Trustnet: Chequebooks at the ready: Biotech is on the shopping list
This is Money: The biotech fund backing companies that could change how we live
Citywire: IBT moved to AA rating for the first time
Citywire: IBT feature on healthcare trust picks
Kepler Market Matters Podcast: IBT's Ailsa Craig
Kepler: Talking Trusts - Interview with Ailsa Craig and Marek Poszepczynski
Investment Week: Biotech innovation will overcome policy noise
Trustnet: The sector-specific trusts consistently outperforming for Sharpe ratio
Kepler: Half Year Results Analysis
Trustnet: Six ISA trust picks for all tastes
James Carthew: Am I too late to switch biotech trust?
Kepler Special Report: Investing in Biotech with Investment Trusts

Investment Manager's Blog

Documents

Document Archive
AGM Results 2025
Change of Auditors
AIFM Disclosure Statement
Terms of Reference: Management Engagement Committee
Terms of Reference: Nomination Committee
Terms of Reference: Audit Committee